Key result
Intensive lipid lowering to LDL-C /dL fails to prevent vulnerable plaque progression to ACS.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Persistent vulnerable plaques despite LDL-C 51 mg/dL warrant caution assuming stabilization; leaves open need for adjunctive therapies in ACS.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Miura et al. (2026) conducted a case report in Acute Coronary Syndrome (n=1). Evolocumab and rosuvastatin was evaluated. Despite 7 months of intensive lipid-lowering therapy achieving an LDL-C of /dL, vulnerable plaque morphology persisted and led to acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: